Cited by 72Protein Degradation and InhibitorsChemical Synthesis and AnalysisUbiquitin and proteasome pathways

The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.

Monomeric Targeted Protein Degraders

Hanan, Emily J., Liang, Jun, Wang, Xiaojing, Blake, Robert A., Blaquiere, Nicole, Staben, Steven T.·2020·Journal of Medicinal Chemistry

DOI 10.1021/acs.jmedchem.0c00093

Open this paper in CoChat — free account

Abstract

The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chemistry. Inducing degradation of a target protein presents several advantages relative to simple inhibition including a potential for extended duration of action and more profound pharmacology. While engineered heterodimeric molecules have recently been a major focus within industry and academia, this Perspective highlights examples of targeted protein degradation observed for smaller, monomeric molecules. Methods and tools for evaluating protein degradation as well as a discussion of physical properties of monomeric vs engineered heterodimeric degraders are presented.

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.0c00093

Cites

218 of 218 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
The Epigenomics of Cancer
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties
Ertl, P., Rohde, B., & Selzer, P. M. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,149
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,785
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524

Show all 218 references

Research works printed but not linked: 2

Towbin, 1989, Immunoblotting in the Clinical Laboratory, J. Clin. Chem. Clin. Biochem., 27, 495
Buchser, 2004, Assay Development Guidelines for Image-Based High Content Screening, High Content Analysis and High Content Imaging

Sorted by citations

Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 674
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220965528 · Cited by 404
Targeted protein degradation via intramolecular bivalent glues
Hsia, O., Hinterndorfer, M., Cowan, A. D., Iso, K., Ishida, T., Sundaramoorthy, R., Nakasone, M. A., Imrichova, H., Schätz, C., Rukavina, A., et al. (2024) · Nature · doi:10.1038/s41586-024-07089-6 · Cited by 222
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Reimagining Druggability Using Chemoproteomic Platforms
Spradlin, J. N., Zhang, E., & Nomura, D. K. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00065 · Cited by 176
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
Hanan, E. J., Braun, M., Heald, R. A., MacLeod, C., Chan, C. C. C., Clausen, S., Edgar, K. A., Eigenbrot, C. W., Elliott, R. L., Endres, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01422 · Cited by 171
Self-citation
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
Design principles for cyclin K molecular glue degraders
Kozicka, Z., Suchyta, D. J., Focht, V., Kempf, G., Petzold, G., Jentzsch, M., Zou, C., Di Genua, C., Donovan, K. A., Coomar, S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01409-z · Cited by 113
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Protein degradation technology: a strategic paradigm shift in drug discovery
Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X., & Qin, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01146-7 · Cited by 96
CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16
Shergalis, A. G., Marin, V. L., Rhee, D. Y., Senaweera, S., McCloud, R. L., Ronau, J. A., Hutchins, C. W., McLoughlin, S. M., Woller, K. R., Warder, S. E., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00747 · Cited by 78
Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216
Teng, M., Lu, W., Donovan, K. A., Sun, J., Krupnick, N. M., Nowak, R. P., Li, Y.-D., Sperling, A. S., Zhang, T., Ebert, B. L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01832 · Cited by 63
The rise of degrader drugs
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 63
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Huang, X., Wu, F., Ye, J., Wang, L., Wang, X., Li, X., & He, G. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.010 · Cited by 62
Self-citation
Prospecting for molecular glues
den Besten, W., & Lipford, J. R. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0620-z · Cited by 55
Improved Proteomics-Based Drug Mechanism-of-Action Studies Using 16-Plex Isobaric Mass Tags
Zinn, N., Werner, T., Doce, C., Mathieson, T., Boecker, C., Sweetman, G., Fufezan, C., & Bantscheff, M. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00900 · Cited by 49
Molecular glues to stabilise protein–protein interactions
Soini, L., Leysen, S., Davis, J., & Ottmann, C. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102169 · Cited by 49
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
Cheng, H., Orr, S. T. M., Bailey, S., Brooun, A., Chen, P., Deal, J. G., Deng, Y., Edwards, M. P., Gallego, G. M., Grodsky, N. B., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01652 · Cited by 46
Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
Scholes, N. S., Mayor‐Ruiz, C., & Winter, G. E. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.007 · Cited by 44
Recent advances in targeted protein degraders as potential therapeutic agents
Yang, N., Kong, B., Zhu, Z., Huang, F., Zhang, L., Lu, T., Chen, Y., Zhang, Y., & Jiang, Y. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10606-w · Cited by 44
Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
Rudolph, J., Settleman, J., & Malek, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0260 · Cited by 42
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38
Current strategies for improving limitations of proteolysis targeting chimeras
Pu, C., Wang, S., Liu, L., Feng, Z., Zhang, H., Gong, Q., Sun, Y., Guo, Y., & Li, R. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107927 · Cited by 32
Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms
Rodriguez-Rivera, F. P., & Levi, S. M. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00389 · Cited by 30
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787 · Cited by 30
B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas
Gu, H., He, J., Li, Y., Mi, D., Guan, T., Guo, W., Liu, B., & Chen, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01433 · Cited by 29
T herapeutic targeting of chromatin: status and opportunities
Siklos, M. I., & Kubicek, S. (2021) · FEBS Journal · doi:10.1111/febs.15966 · Cited by 28
Multimodal small-molecule screening for human prion protein binders
Reidenbach, A. G., Mesleh, M. F., Casalena, D. E., Vallabh, S. M., Dahlin, J. L., Leed, A., Chan, A. I., Usanov, D. L., Yehl, J., Lemke, C. T., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014905 · Cited by 26
A blood–brain penetrant RNA-targeted small molecule triggers elimination of r(G 4 C 2 ) exp in c9ALS/FTD via the nuclear RNA exosome
Bush, J. A., Meyer, S. M., Fuerst, R., Tong, Y., Li, Y., Benhamou, R. I., Aikawa, H., Zanon, P. R. A., Gibaut, Q. M. R., Angelbello, A. J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210532119 · Cited by 23
Structure driven compound optimization in targeted protein degradation
Leissing, T. M., Luh, L. M., & Cromm, P. M. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.005 · Cited by 22
The “three body solution”: Structural insights into molecular glues
Tomlinson, A. C. A., Knox, J. E., Brunsveld, L., Ottmann, C., & Yano, J. K. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103007 · Cited by 20
Monovalent pseudo-natural products supercharge degradation of IDO1 by its native E3 KLHDC3
Hennes, E., Lucas, B., Scholes, N. S., Cheng, X., Scott, D. C., Bischoff, M., Reich, K., Gasper, R., Lucas, M., Xu, T. T., et al. (2026) · Nature Chemistry · doi:10.1038/s41557-025-02021-5 · Cited by 20
Primary Amine Tethered Small Molecules Promote the Degradation of X-Linked Inhibitor of Apoptosis Protein
den Besten, W., Verma, K., Yamazoe, S., Blaquière, N., Phung, W., Izrael-Tomasevic, A., Mulvihill, M. M., Helgason, E., Prakash, S., Goncharov, T., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05269 · Cited by 20
Self-citation
Small-Molecule Approaches to Target Transcription Factors
Cui, H., Stilgenbauer, M., & Koehler, A. N. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-012209 · Cited by 19
Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity
Huang, Y., Liu, W., Zhao, C., Shi, X., Zhao, Q., Jia, J., & Wang, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116547 · Cited by 19
Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics
Zhao, W., Jiang, Y., Li, X., & Wang, H. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2020 · Cited by 19
Exploring Ligand-Directed N-Acyl-N-alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degrader Development
Teng, M., Jiang, J., Ficarro, S. B., Seo, H., Bae, J. H., Donovan, K. A., Fischer, E. S., Zhang, T., Dhe‐Paganon, S., Marto, J. A., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00285 · Cited by 18
New class of molecule targets proteins outside cells for degradation
Whitworth, C., & Ciulli, A. (2020) · Nature · doi:10.1038/d41586-020-02211-w · Cited by 16
Transcription factors in the development and treatment of immune disorders
Drinan, S. D., Bass, J. I. F., & Bass, J. I. F. (2023) · Transcription · doi:10.1080/21541264.2023.2294623 · Cited by 15
Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model
Thankan, R. S., Thomas, E. B., Purushottamachar, P., Weber, D. J., & Njar, V. C. O. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106700 · Cited by 14
Emerging mechanisms of targeted protein degradation by molecular glues
Frere, G. A., de Araujo, E. D., & Gunning, P. T. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.01.001 · Cited by 13
Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer
Wang, A., Luo, X., Meng, X., Lu, Z., Chen, K., & Yang, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00880 · Cited by 11
Rational Design of Methylene Blue–Raloxifene Conjugates for Efficient Breast Tumor Elimination Triggered by ERα Degradation
Zhang, Y., Yu, Q., Wang, Z., Qing, L., Mo, X., Liu, B., Chai, Y., Yu, B., Dong, Y., Pan, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00490 · Cited by 10
Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity
Boudreau, M. W., & Hergenrother, P. J. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00110a · Cited by 10
Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
Zhao, C., Wang, H., Zhan, W., Lv, X., & Ma, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00079 · Cited by 9
Molecular Glue Degraders: From Serendipity to Hunting and Design
Nieto‐Barrado, L., Domostegui, A., & Mayor‐Ruiz, C. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch6 · Cited by 7
Fine-Tuning of Nitrogen-Containing Bisphosphonate Esters that Potently Induce Degradation of HMG-CoA Reductase
Kawamura, K., YOSHIOKA, H., Sato, C., Yajima, T., Furuyama, Y., Kuramochi, K., & Ohgane, K. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117145 · Cited by 5
Allosteric Inhibitors of the SARS-COV-2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3
Cockram, P. E., Walters, B. T., Lictao, A., Shanahan, F., Wertz, I. E., Foster, S. A., & Rudolph, J. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00312 · Cited by 4
Structure-Property Relationships Reported for the New Drugs Approved in 2024
Choi, K. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575390155250711072709 · Cited by 3
Discovery of 2,5-diaminopyrimidine derivatives as the first series of selective monomeric degraders of B-lymphoid tyrosine kinase
Fu, T., Zuo, Y., Xue, G., Zhou, D., & Pan, Z. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115460 · Cited by 2
Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction
Fischer, F., Temml, V., & Schuster, D. (2025) · Molecules · doi:10.3390/molecules30102183 · Cited by 1
Double whammy: drugs that inhibit kinase enzymes also speed up their disposal
(2025) · Nature · doi:10.1038/d41586-025-03816-9 · Cited by 1
Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras
Chen, M., Li, Y., Wei, X., Fu, Q., He, C., Li, Z., Gu, M., Peng, X., & Shi, P. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01778 · Cited by 1
Spherical POV LED display using PIC 16F628
Gunawan, T. S., & Ahmad, M. O. (2011) · IIUM Press eBooks
"El soneto a Granada" de Pablo Antonio Cuadrado
Urbina, N. (2010) · Hispanic poetry review
Stability of Steroid Hormone Receptors
Gale-Day, Z. J., & Gestwicki, J. E. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch2
Drug Properties
Khojasteh, S. C., Wong, H., Zhang, D., & Hop, C. E. C. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-10691-0_2
Research progress in small-molecule modulators of protein-protein interactions
Yang, B., & Qi, X. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0034
Gluing the pieces together
Kozicka, Z. (2023) · Science · doi:10.1126/science.adl4288
Identification and SAR optimization of FBXO22-mediated TEAD Targeted Glue™ degradersPreprint
Fisher, M., Fletcher, A., Hamby, C., Miles, J., Ambler, M., Azevedo, A., Bisetto, S., Davies, C. T. R., Drouhin, P., Greger, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719895
Targeted protein degradation: mechanistic diversity, therapeutic expansion, and clinical translation
Wang, C., Guo, Z., Liu, Y., Gao, Q., Wang, Q., Liu, Y., & Liu, Y. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127323
AI-Driven Multi-Omics Integration of Synthetic Colon Adenocarcinoma for Cluster-Guided PROTAC Candidate Design Targeting KRASG12D
Elamin, K. M., Elbashir, S. M. I., & Adam, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177511
BindingDB Entry 50021951: Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.
BindingDB (2025) · UC San Diego · doi:10.7270/q2vh5th3
BindingDB Entry 50018610: Fine-tuning of nitrogen-containing bisphosphonate esters that potently induce degradation of HMG-CoA reductase.
BindingDB (2024) · UC San Diego · doi:10.7270/q2d50s5t
BindingDB Entry 50017491: Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
BindingDB (2023) · UC San Diego · doi:10.7270/q2s46x11
BindingDB Entry 50020396: Discovery of 2,5-diaminopyrimidine derivatives as the first series of selective monomeric degraders of B-lymphoid tyrosine kinase.
BindingDB (2024) · UC San Diego · doi:10.7270/q20c517v
BindingDB Entry 50019573: Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer.
BindingDB (2024) · UC San Diego · doi:10.7270/q2736w8f
BindingDB Entry 50017482: B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.
BindingDB (2023) · UC San Diego · doi:10.7270/q2jm2fpw
BindingDB Entry 50020203: Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues.
BindingDB (2024) · UC San Diego · doi:10.7270/q2z60tgk
BindingDB Entry 50023590: Rational Design of Methylene Blue-Raloxifene Conjugates for Efficient Breast Tumor Elimination Triggered by ERα Degradation.
BindingDB (2026) · UC San Diego · doi:10.7270/q2183cgn
BindingDB Entry 50012357: Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
BindingDB (2022) · UC San Diego · doi:10.7270/q2th8rc9

Authors: Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T.
Affiliations: Genentech (US)
Genentech, Inc. , , 1 DNA Way , , ,
Corresponding author: Staben, Steven T.
ORCID: Hanan, Emily J.
Liang, Jun
Wang, Xiaojing
Staben, Steven T.
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 2020-04-30
Volume: 63
Issue: 20
Pages: 11330-11361
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/acs.jmedchem.0c00093
OpenAlex: W3023538604
Cited by: 69
References: 218
Citations by year: 2026: 6 · 2025: 6 · 2024: 8 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 8
FWCI: 1.20
Type: journal article
Language: en
Open access: closed
Licence: doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-045 (stm-asf)
Locations: Journal of Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords: targeted protein degradation, duration of action
MeSH terms: Binding Sites, Humans, Protein Binding, Proteins, Molecular Structure, Ubiquitin-Protein Ligases, Cell Line, Tumor, Small Molecule Libraries, Drug Discovery, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Monomeric Targeted Protein Degraders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks